# Synthego

high-quality sgRNA synthesis and turnkey cell engineering.

Source: https://en.bioecon.ru/companies/synthego/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2012 | https://bondoro.com/synthego/, https://elevenflo.com/blog/synthego-corporation |
| Headquarters | Redwood City, CA | https://bondoro.com/synthego/, https://www.cirm.ca.gov/wp-content/uploads/2025/03/Synthego-summary-sheet.pdf |
| Funding | Exceeded $450 million in total funding prior to Chapter 11 filing | https://bondoro.com/synthego/, https://elevenflo.com/blog/synthego-corporation |
| Production site | 3696 Haven Ave (Suite A and C) and 955 Charter Street, Redwood City, CA | https://www.cirm.ca.gov/wp-content/uploads/2025/03/Synthego-summary-sheet.pdf |
| Capacity | GMP facility (18,000+ sq ft) has 100g+ annual capacity; RUO and INDe facility (40,000+ sq ft) has 10g+ annual capacity for INDe | https://www.cirm.ca.gov/wp-content/uploads/2025/03/CIRM_Synthego-deck.pdf, https://www.cirm.ca.gov/wp-content/uploads/2025/03/Synthego-summary-sheet.pdf |
| Certification | ISO 9001:2015 certified; GMP manufacturing adheres to FDA/ICH guidelines and ISO 13485 conditions | https://www.cirm.ca.gov/wp-content/uploads/2025/03/Synthego-summary-sheet.pdf, https://www.synthego.com/cgmp-crispr-quality/, https://www.synthego.com/cgmp-crispr-solutions/ |
| Headcount | Approximately 150 employees as of May 2025 petition date [medium confidence] | https://bondoro.com/synthego/ |
| Revenue | Revenue growth observed 2020-2023, but the company never reached profitability and entered Chapter 11 bankruptcy in 2025 [medium confidence] | https://bondoro.com/synthego/, https://elevenflo.com/blog/synthego-corporation |

Independent sources: bondoro.com, cirm.ca.gov, elevenflo.com

## Technologies

- [CRISPR screening as a service](https://en.bioecon.ru/technology/crispr-screening-as-a-service/)